Fibrocell reports on interim results and progress of phase 1/2 clinical trial of FCX-007
Fibrocell provided an update on the interim results and progress of its Phase 1/2 clinical trial of FCX-007 for treatment of recessive dystrophic epidermolysis bullosa. Safety data from these patients show FCX-007 was well-tolerated up to 52 weeks post-administration. May 21, 2018